Vedolizumab treatment in adults with immunodeficiency-associated enteropathy: a case series
4 affiliations
- 1Immunology Section, Hospital Italiano de Buenos Aires
- 2Internal Medicine Department, Hospital Italiano de Buenos Aires
- 3Gastroenterology Section, Hospital Italiano de Buenos Aires
- 4Pathology Department, Hospital Italiano de Buenos Aires
Abstract
Background: Inflammatory gastrointestinal disease is a common manifestation of inborn errors of immunity (IEI) and may affect any segment of the gastrointestinal tract. Vedolizumab, a gut-selective anti-integrin approved for inflammatory bowel disease, has been scarcely studied in IEI. We describe our experience with vedolizumab in adults with immunodeficiency-associated enteropathy.
Methods: We conducted a retrospective case series of adults with humoral or combined immunodeficiency and inflammatory gastrointestinal disease treated with vedolizumab at a single tertiary referral center. Clinical, endoscopic, laboratory and histopathological responses were assessed.
Results: Four adult patients with immunodeficiency-associated enteropathy received vedolizumab. Two patients achieved sustained clinical and endoscopic/histological remission, both of whom had predominant villous atrophy (one with TRAF3 haploinsufficiency, and the other had multiple autoimmune manifestations, refractory immune thrombocytopenia and agammaglobulinemia following rituximab). Another patient with combined immunodeficiency and protein-losing enteropathy had marked clinical improvement with mild histologic response, but relapsed at two years in the setting of norovirus and Clostridium difficile infection. In contrast, a woman with common variable immunodeficiency, autoimmune hepatitis, and severe refractory pancolitis failed to respond to vedolizumab and subsequently developed CMV superinfection, requiring treatment escalation.
Conclusions: In this case series, vedolizumab was associated with clinical improvement predominantly in patients with villous atrophy rather than refractory colitis. These findings are hypothesis-generating and support further evaluation of vedolizumab as a therapeutic option for selected patients with immunodeficiency-associated enteropathy.
Related
- Associations between redox-related biomarkers and treatment response in patients with inflammatory bowel disease initiating infliximab or vedolizumab
- Chronic Enteropathy Associated With SLCO2A1 Gene Mutation; Initially Misdiagnosed as Fibrostenosing Crohn's Disease
- Refractory Pseudomonas aeruginosa Bronchopulmonary Infection After Lung Transplantation for Common Variable Immunodeficiency Despite Maximal Treatment Including IgM/IgA-Enriched Immunoglobulins and Bacteriophage Therapy
- Case report: Maternal engraftment of T-cells in a patient with Severe Combined Immunodeficiency due to DCLRE1C pathogenic variant - diagnostic and treatment challenges
- Burden of treatment associated with hearing aid use among older adults with hearing loss: a qualitative study.
BibTeX
@article{angarola2026vedolizumab,
title = {{Vedolizumab treatment in adults with immunodeficiency-associated enteropathy: a case series}},
author = {Ernestina Angarola and María Josefina Etchevers and Juan Andres De Paula and Maria Florencia Sanchez and Juan Pablo Santino and Diana Liberatore},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1953966},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1953966/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Vedolizumab treatment in adults with immunodeficiency-associated enteropathy: a case series
AU - Ernestina Angarola
AU - María Josefina Etchevers
AU - Juan Andres De Paula
AU - Maria Florencia Sanchez
AU - Juan Pablo Santino
AU - Diana Liberatore
PY - 2026
DA - 2026/10/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1953966
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1953966/full
AB - Background: Inflammatory gastrointestinal disease is a common manifestation of inborn errors of immunity (IEI) and may affect any segment of the gastrointestinal tract. Vedolizumab, a gut-selective anti-integrin approved for inflammatory bowel disease, has been scarcely studied in IEI. We describe our experience with vedolizumab in adults with immunodeficiency-associated enteropathy. Methods: We conducted a retrospective case series of adults with humoral or combined immunodeficiency and inflammatory gastrointestinal disease treated with vedolizumab at a single tertiary referral center. Clinical, endoscopic, laboratory and histopathological responses were assessed. Results: Four adult patients with immunodeficiency-associated enteropathy received vedolizumab. Two patients achieved sustained clinical and endoscopic/histological remission, both of whom had predominant villous atrophy (one with TRAF3 haploinsufficiency, and the other had multiple autoimmune manifestations, refractory immune thrombocytopenia and agammaglobulinemia following rituximab). Another patient with combined immunodeficiency and protein-losing enteropathy had marked clinical improvement with mild histologic response, but relapsed at two years in the setting of norovirus and Clostridium difficile infection. In contrast, a woman with common variable immunodeficiency, autoimmune hepatitis, and severe refractory pancolitis failed to respond to vedolizumab and subsequently developed CMV superinfection, requiring treatment escalation. Conclusions: In this case series, vedolizumab was associated with clinical improvement predominantly in patients with villous atrophy rather than refractory colitis. These findings are hypothesis-generating and support further evaluation of vedolizumab as a therapeutic option for selected patients with immunodeficiency-associated enteropathy.
SN - 1664-3224
ER -